Pipeline

Advancing transformative medicines
for neurological diseases.

 

Neurologic diseases – which are estimated to impact more than 1 billion people globally – represent a significant burden on those who suffer from them, on their families and communities, and on the healthcare system.

Thanks to significant advances in human genetics and genomics, we now understand the molecular causes of many neurological diseases and know how to target them.

Our pipeline includes medicines targeting the genetics underlying multiple neurological diseases.

MECHANISM / INDICATION

Early Research

Late Research

IND-Enabling

Phase I

WHOLLY-OWNED PIPELINE

+ Anti-tau Antibody (VY-TAU01) / Alzheimer’s Disease

+ SOD1 Silencing Gene Therapy (siRNA) / ALS

+ Tau Silencing Gene Therapy (siRNA) / Alzheimer’s Disease

+ Anti-Aβ Gene Therapy (Vectorized Antibody) / Alzheimer’s Disease

Early Research

Late Research

IND-Enabling

Phase I

PARTNERSHIPS (REIMBURSED)

GBA1 Gene Therapy / Parkinson’s/Other
Neurocrine (VYGR has 50% co/co option)
FXN Gene Therapy / Friedreich’s Ataxia
Neurocrine (VYGR has 40% co/co option)

Five Gene Therapy Programs / Undisclosed Diseases
Neurocrine

Undisclosed

Huntington’s Gene Therapy / Huntington’s Disease
Novartis

Undisclosed

CAPSID LICENSES

Gene Therapy / Rare Neurological Disease

Alexion, AstraZeneca Rare Disease License

Three Gene Therapy Programs / SMA + CNS Diseases

Novartis Licenses

Gene Therapy / Prion Disease

Sangamo License

One of the most significant challenges in neurotherapeutics remains developing medicines that can cross the blood-brain barrier and hit their targets. To address this problem, Voyager has discovered novel capsids and identified associated receptors that potentially enable exceptional delivery across the blood-brain barrier following intravenous dosing.

Patient Resources

One of Voyager’s core values is “Patients First.” This means we act with urgency and drive every decision with the knowledge that patients are waiting for us.

Photo: Klaus C., living with ALS, 2023

Partners

Our allies in realizing the potential of neurogenetic medicines